AbCellera Biologics (ABCL) Stock Forecast & Price Target

$2.67 -0.04 (-1.48%)

(As of 11/20/2024 ET)

AbCellera Biologics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for AbCellera Biologics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a buy rating for ABCL.

Consensus Price Target

$8.67
224.59% Upside

According to the 3 analysts' twelve-month price targets for AbCellera Biologics, the average price target is $8.67. The highest price target for ABCL is $12.00, while the lowest price target for ABCL is $5.00. The average price target represents a forecasted upside of 224.59% from the current price of $2.67.

Get the Latest News and Ratings for ABCL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbCellera Biologics and its competitors.

ABCL Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)	9 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$8.67	$10.33	$14.20	$21.88
Forecasted Upside	224.59% Upside	263.85% Upside	444.06% Upside	393.79% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

ABCL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABCL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbCellera Biologics Stock vs. The Competition

Type	AbCellera Biologics	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	224.59% Upside	26,931.55% Upside	9.81% Upside
News Sentiment Rating	Very Positive News See Recent ABCL News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	Benchmark 2 of 5 stars	R. Wasserman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
11/5/2024	Stifel Nicolaus 4 of 5 stars		Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $12.00	+341.18%
7/11/2024	KeyCorp 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $5.00	+78.57%
11/3/2023	Bloom Burton Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Martin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
10/13/2023	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight	$20.00	+402.51%
8/4/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$27.00 ➝ $24.00	+278.55%
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$16.00 ➝ $15.00	+150.84%
2/28/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
2/22/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$34.00	+282.45%
2/22/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$40.00 ➝ $32.00	+259.95%
1/6/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$20.00 ➝ $18.00	+89.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:31 AM ET.

ABCL Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for AbCellera Biologics is $8.67, with a high forecast of $12.00 and a low forecast of $5.00.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABCL shares.
: According to analysts, AbCellera Biologics's stock has a predicted upside of 224.59% based on their 12-month stock forecasts.
: AbCellera Biologics has been rated by research analysts at Benchmark, and Stifel Nicolaus in the past 90 days.
: Analysts like AbCellera Biologics less than other "medical" companies. The consensus rating score for AbCellera Biologics is 2.67 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ABCL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

This page (NASDAQ:ABCL) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Stock Forecast & Price Target